
    
      This Bridging Extension is to determine if intravenous CD101 is safe [Day 45- 52 for subjects
      with candidemia only, or Day 52- 59 for subjects with invasive candidiasis with or without
      candidemia] and effective [Day 14 (Â± 1 day)] in the treatment of candidemia and/or invasive
      candidiasis when compared to caspofungin (followed by oral fluconazole).
    
  